Irinotecan

N-acetyl cysteine and ATP were purchased from Sigma, Glutathione monoethyl ester from Calbiochem, KH7 and SQ22536, forskolin, Inhibitor-172, MK571 and irinotecan were purchased from Tocris. [¹⁴C] 6-Mercaptopurine (6-MP) (51 mCi/mmol) was derived from Moravek Biochemicals, CA. ADCY1, 3,6,7,9 and10 adenylyl cyclase antibodies were purchased from Abcam.

Temozolomide (Sigma-Aldrich, Hamburg, Germany)
Irinotecan (Tocris, Wiesbaden, Germany)
PI-103 (Cayman Chemical, Mi, USA)

Human pancreatic cancer cells such as PANC1 and AsPC-1 (ATCC, Manassas, VA, USA), as well as PANC10.05, PANC198, and Pa03C (obtained from Dr. A. Maitra at MD Anderson Cancer Center, Houston, TX, USA), were cultured in DMEM (Corning, New York, NY, USA). Human mesenchymal stem cells (MSCs) (#PT-2501, Lonza, Basel, Switzerland) were grown in MSCBM (#PT-3238, Lonza). Jurkat T lymphocytes and PC-3 human prostate cancer cells (ATCC) were cultured in RPMI1640. The culture medium was enriched with 10% fetal bovine serum (FBS) and 1% antibiotics, and cells were incubated at 37 °C in a 5% CO₂ atmosphere. Cells were treated with 20 µM CW008 (#5495, Tocris Bioscience, Minneapolis, MN, USA) as an activator of PKA signaling [29 (link)] or 50 µM of Dorsomorphin (#3093, Tocris Bioscience) as an inhibitor of AMPK signaling [30 (link)] for one day. Tumor cells were treated with 2 µg/mL of recombinant PSCA proteins (#MBS2012408; MyBioSource, San Diego, CA, USA), or chemotherapeutic agents, such as Irinotecan (#2688, Tocris Bioscience), 5-Fluorouracil (#3257, Tocris Bioscience), and Oxaliplatin (#2623, Tocris Bioscience).